Let me first state my personal stance: not very interested. I didn't originally plan to post this article, but then realized it's been almost half a month since I last wrote something, and I really felt like I was letting everyone down... So tonight, I'll take some time and write one!
The industry sector is good, but the company itself isn't outstanding yet—it’s still a B-share. The fluctuation of these kinds of B-shares is quite hard to gauge. Previously, I had high hopes for Brii Biosciences, which ended up giving me quite a psychological blow.
I now feel resistant towards B-shares. In the previous batch of new stocks, I placed Brii Biosciences-B at the highest priority for subscription, but its price dropped below the issue price in the gray market. On its first trading day, it only rose by 3.15%, yet today its cumulative gain has reached 79.78%. Unfortunately, I sold it too early... It was truly tormenting.
Today, the margin financing suddenly exploded, with statistics showing 134 times oversubscription, and the actual number definitely exceeded 200 times. Market sentiment is still good—perhaps because everyone has been holding back for too long. Recently, the broader market performance has been decent, combined with the myth of medical device companies never losing, and brokerages releasing high multiples of margin financing. All these factors have contributed to this result.
You can arrange based on your own capital plans: those with more money can participate in the subscription; those with less might as well skip it. Here are a few simple reasons:
1. Valuation space.
Shanghai Heart玮 Medical Technology Co., Ltd., established in June 2016, is an innovative neuro-interventional medical device company. The offering price is between HK$160-171, corresponding to a market value of HK$6.214 billion to HK$6.641 billion. The H-share floating market cap is HK$5.397 billion...